Laurus Labs receives gViread approval, unit clears USFDA inspection

Aurobindo Pharma, Cipla, Hetero Drugs, Macleods, Strides, etc. also have approval for gViread. The news is positive on the counter.

Mar 05, 2018 03:03 IST India Infoline News Service

Laurus Labs
Laurus Labs has announced that its Unit 2 (formulations) has completed USFDA audit with zero form 483 observations. This inspection was carried out from February 26 to March 1, 2018.

Laurus Labs has also announced that it has received first ANDA approval for Tenofovir Disoproxil Fumarate Tablets 300mg. Tenofovir Disoproxil Fumarate is therapeutically equivalent to Gilead Sciences’ drug Viread, which is used for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older.

Aurobindo Pharma, Cipla, Hetero Drugs, Macleods, Strides, etc. also have approval for gViread. The news is positive on the counter.

Laurus Labs Ltd is currently trading at Rs540.50 up by Rs8 or 1.5% from its previous closing of Rs532.50 on the BSE. The scrip opened at Rs547.50 and has touched a high and low of Rs547.50 and Rs539.20 respectively. The stock is currently trading above its 200 DMA.

Related Story